Differentiation of innovation strategies based on pharmaceutical licensing agreements: Insight from Korean pharmaceutical firms

ABSTRACT The paper aims to show how licensing behaviour can be used to differentiate distinct innovation strategies. Information on in-licensing and out-licensing agreements is used to guide the development of a framework that details the licensing firm’s relational preference for internal and external orientation. Using firm-level data of the Korean pharmaceutical firms, the study categorised the distinct strategic orientations of firms based on the proposed matrix model. The results indicated that firms with higher R&D (research and development) expenditures have a tendency to greater external exploitation of technological knowledge than firms with low R&D spending. The study provides potential avenues for targeting of licensing partners from the perspective of firms seeking to in-license or out-license their innovations.

[1]  Country report (Korea) , 2020, 2020 23rd Conference of the Oriental COCOSDA International Committee for the Co-ordination and Standardisation of Speech Databases and Assessment Techniques (O-COCOSDA).

[2]  Chie Hoon Song,et al.  Mapping the Patent Landscape in the Field of Personalized Medicine , 2017, Journal of Pharmaceutical Innovation.

[3]  Yitao Wang,et al.  Obstacles and opportunities in Chinese pharmaceutical innovation , 2017, Globalization and Health.

[4]  Sungwoong Hwang,et al.  Middle-ground players in dynamic imitative markets: global entry strategies of Korean firms in the biosimilars market , 2017, Technol. Anal. Strateg. Manag..

[5]  Jens Leker,et al.  Anticipation of converging technology areas — A refined approach for the identification of attractive fields of innovation , 2017 .

[6]  John Qi Dong,et al.  Being Central Is a Double-Edged Sword: Knowledge Network Centrality and New Product Development in U.S. Pharmaceutical Industry , 2016 .

[7]  Seungmin Kim,et al.  How knowledge flow affects Korean ICT manufacturing firm performance: a focus on open innovation strategy , 2016, Technol. Anal. Strateg. Manag..

[8]  M. Reichman,et al.  Open innovation in early drug discovery: roadmaps and roadblocks. , 2016, Drug discovery today.

[9]  Wonjoon Kim,et al.  Identifying the structure of knowledge networks in the US mobile ecosystems: patent citation analysis , 2016, Technol. Anal. Strateg. Manag..

[10]  Taeyong Yang,et al.  How technological innovation affects the structure of an industry: entrepreneurship evolution in the biotechnology and pharmaceutical industry since 1980 , 2016, Technol. Anal. Strateg. Manag..

[11]  Ulrich A. K. Betz,et al.  The Pharmaceutical Industry is Opening Its R&D Boundaries , 2016 .

[12]  O. Gassmann,et al.  Value Creation in the Pharmaceutical Industry: The Critical Path to Innovation , 2016 .

[13]  Munjae Lee Impact of Corporate Governance on Research and Development Investment in the Pharmaceutical Industry in South Korea , 2015, Osong public health and research perspectives.

[14]  A. Yawson,et al.  R&D intensity, cross-border strategic alliances, and valuation effects , 2015 .

[15]  Thomas Scherngell,et al.  R&D internationalisation patterns in the global pharmaceutical industry: evidence from a network analytic perspective , 2015, Technol. Anal. Strateg. Manag..

[16]  Peter Robbins,et al.  Innovating the Innovation Process: An Organisational Experiment in Global Pharma Pursuing Radical Innovation , 2015 .

[17]  M. Rocío Martínez-Torres,et al.  Analysis of open innovation communities from the perspective of social network analysis , 2014, Technol. Anal. Strateg. Manag..

[18]  L. Trigeorgis,et al.  The Role of Growth Options in Explaining Stock Returns , 2014, Journal of Financial and Quantitative Analysis.

[19]  Oliver Plum,et al.  Comparing knowledge networking in different knowledge bases in Germany , 2011 .

[20]  Benjamin Hughes,et al.  Knowledge Arbitrage in Global Pharma: A Synthetic View of Absorptive Capacity and Open Innovation , 2010 .

[21]  J. DiMasi,et al.  Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs , 2010, Clinical pharmacology and therapeutics.

[22]  Susie Stephens,et al.  Is open innovation the way forward for big pharma? , 2010, Nature Reviews Drug Discovery.

[23]  O. Gassmann,et al.  Open R&D and Open Innovation: Exploring the Phenomenon , 2009 .

[24]  J. Alegre,et al.  Analysing the link between export intensity, innovation and firm size in a science-based industry , 2007 .

[25]  James Mittra,et al.  Life Science Innovation and the Restructuring of the Pharmaceutical Industry: Merger, Acquisition and Strategic Alliance Behaviour of Large Firms , 2007, Technol. Anal. Strateg. Manag..

[26]  Nadine Roijakkers,et al.  Inter-firm R&D partnering in pharmaceutical biotechnology since 1975: Trends, patterns, and networks , 2006 .

[27]  B. Dousset Innovation and network structural dynamics: Study of the alliance network of a major sector of the biotechnology industry , 2005 .

[28]  Amanda Langley,et al.  Grand strategies and strategic actions in the pharmaceutical industry 2001–2002 , 2005, Technol. Anal. Strateg. Manag..

[29]  Oliver Gassmann,et al.  Organizing Pharmaceutical Innovation: From Science‐based Knowledge Creators to Drug‐oriented Knowledge Brokers , 2005 .

[30]  Andrew D. James,et al.  The Strategic Management of Mergers and Acquisitions in the Pharmaceutical Industry: Developing a Resource-based Perspective , 2002, Technol. Anal. Strateg. Manag..

[31]  Massimo Riccaboni,et al.  Technological change and network dynamics: Lessons from the pharmaceutical industry , 2001 .

[32]  Charles Oppenheim,et al.  Patent citation analysis , 1997, Scientometrics.

[33]  Kyung-Nam Kang,et al.  Influence of government R&D support and inter-firm collaborations on innovation in Korean biotechnology SMEs , 2012 .

[34]  V. Chiesa,et al.  Organisational modes for Open Innovation in the bio-pharmaceutical industry: An exploratory analysis , 2011 .

[35]  H. Chesbrough The Era of Open Innovation , 2003 .

[36]  Vladimir Batagelj,et al.  Centrality in Social Networks , 1993 .

[37]  Jinjoo Lee,et al.  Innovation strategy of local pharmaceutical firms in Korea: a multivariate analysis , 1989 .

[38]  L. Freeman,et al.  Centrality in social networks: ii. experimental results☆ , 1979 .